EP2705042A1 - Solvate de diméthylformamide rifaximine - Google Patents
Solvate de diméthylformamide rifaximineInfo
- Publication number
- EP2705042A1 EP2705042A1 EP12721936.8A EP12721936A EP2705042A1 EP 2705042 A1 EP2705042 A1 EP 2705042A1 EP 12721936 A EP12721936 A EP 12721936A EP 2705042 A1 EP2705042 A1 EP 2705042A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rifaximin
- solvate
- hours
- process according
- dmf solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention provides a new polymorphic form of rifaximin designated as DMF solvate and the process for its preparation. It also provides a pharmaceutical composition comprising the same and its use for the treatment of bowel related disorders.
- Rifaximin is a semi-synthetic, nonsystemic antibiotic which was disclosed in U.S. Patent No. 4,341,785. It is marketed in the United States under the trade name Xifaxan® for the treatment of Travelers' diarrhea and Hepatic Encephalopathy.
- Rifaximin is designated as (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S, 28E)5,6,21,23,25- pentahydroxy-27-methoxy-2,4, 11 , 16,20,22,24,26-octamethyl-2,7(epoxypenta-deca- [ 1 , 11 , 13]trienimino)benzofuro[4,5-e]pyrido[ 1 ,2-a]-benzimidazole-l,15(2H)dione,25- acetate and is represented by the structural formula as shown below:
- Polymorphism is a property exhibited by several compounds and compound complexes, including pharmaceutical compounds, whether by way of crystal forms or solvates. Different crystalline forms or polymorphs of the same pharmaceutical compounds can have different solubility characteristics, and this, in turn, affects bioavailability.
- the discovery of new polymorphic forms and solvates of a pharmaceutically useful compound provides opportunities to design the performance characteristics of a pharmaceutical product for formulation according to the need. But there is no real way to predict if a compound actually exhibits polymorphism, and if it did what kind of crystal structures it will exhibit. It requires diligent experimentation and analysis.
- WO 2009/108730 mentions Form ⁇ -l to be an ethanolate/trihydrate of rifaximin but does not provide any example/experimental evidence to support it.
- the literature does not provide any specific reference related to the solvated forms of rifaximin.
- the present invention provides ⁇ , ⁇ -dimethylformamide solvate of rifaximin which is free flowing, stable, easily reproducible and suitable to develop formulations.
- the present invention provides a new polymorphic form of rifaximin designated as
- DMF solvate and the process for its preparation. It also provides a pharmaceutical composition comprising the same and its use for the treatment of bowel related disorders.
- the first aspect of the present invention provides DMF solvate of the rifaximin.
- the second aspect of the present invention provides DMF solvate of the rifaximin characterized by d-spacing (A) values selected from 17.79, 12.31, 11.82, 10.54, 6.74, 5.91, 4.70, 4.22, 4.16, 4.06, 3.98 or 3.53.
- A d-spacing
- the third aspect of the present invention provides a process for the preparation of DMF solvate of the rifaximin, the steps comprising of:
- the fourth aspect of the present invention provides substantially pure DMF solvate of the rifaximin having a purity greater than 99%, when measured by HPLC area percentage.
- the present invention provides a pharmaceutical composition comprising DMF solvate of the rifaximin with one or more pharmaceutically acceptable carriers and/or excipients.
- the present invention provides a method for treating, preventing or alleviating bowel related disorders in humans comprising administering to said patient a therapeutically effective amount of DMF solvate of the rifaximin or a pharmaceutical composition comprising the same.
- Figure 1 X-Ray Diffraction (XRD) pattern of DMF solvate of rifaximin
- Ambient temperature refers to temperature ranging from about 15°C to about 30°C.
- substantially pure refers to the DMF solvate of the rifaximin having purity greater than 99%.
- the first aspect of the present invention provides DMF solvate of the rifaximin.
- DMF solvate of the rifaximin having characteristics d-spacing (A) values selected from 17.79, 12.31, 1 1.82, 10.54, 6.74, 5.91, 4.70, 4.22, 4.16, 4.06, 3.98 or 3.53.
- DMF solvate of rifaximin may be characterized by d-spacing (A) values at about 17.79, 14.91, 13.41, 12.31, 11.82, 10.54, 10.13, 8.83, 8.28, 7.86, 7.18, 6.74, 6.42, 6.16, 5.91, 5.71, 5.65, 5.26, 5.10, 4.98, 4.70, 4.50, 4.32, 4.22, 4.16, 4.06, 3.98, 3.83, 3.66, 3.53, 3.39, 3.18, 3.04, 2.95, 2.78 and the corresponding 2-theta values at about 4.97, 5.93, 6.59, 7.18, 7.48, 8.39, 8.73, 10.02, 10.69, 1 1.26, 12.32, 13.14, 13.79, 14.38, 15.00, 15.51, 15.67, 16.85, 17.39, 17.83, 18.90, 19.71, 20.56, 21.04, 21.34, 21.89, 22.32, 23.24, 24.29, 25.22, 26.32, 28.05, 29,39, 30
- DMF solvate of the rifaximin can also be characterized by (i) XRD having substantially the same pattern as depicted in Figure 1, (ii) DSC having substantially the same pattern as depicted in Figure 2, (iii) TGA having substantially the same pattern as depicted in Figure 3.
- the DSC shows two characteristic endotherm peaks.
- the first endothermal peak is in the range from about 45.60°C to about 71.59°C and the second endothermal peak is from about 110.15°C to about 1 11.82°C.
- the DMF solvate of the rifaximin has water content from about 0% to about 5%, when measured by Karl-Fischer analysis. Preferably, water content can be in between 1% to 3%.
- the rifaximin, used herein, for the preparation of DMF solvate can be obtained by any of the methods known in literature such as those described in U.S. Patent Nos.
- the mixture of rifaximin in ⁇ , ⁇ -dimethylformamide solvent may be heated at a temperature of about 45°C to about 60°C followed by optional stirring of the mixture, if required for complete dissolution of the mixture.
- the reaction mixture obtained may be cooled to ambient temperature, preferably to about 20°C to 30°C, followed by stirring.
- the stirring of the cooled mixture can be carried out for long hours, for about 30 hours, preferably for about 12 hours to about 24 hours for complete precipitation of the solid.
- the solid thus formed can be isolated by conventional means known to a person of ordinary skill in the art including, for example, decantation, filtration or centrifugation.
- the isolated solid, designated as DMF solvate of the rifaximin can be washed with solvent if desired, followed by drying, wherein the drying can be carried out by any drying means known to a person of ordinary skill in the art including, for example, under reduced pressure, vacuum tray drying, air drying and/or combinations thereof.
- DMF solvate of rifaximin can be dried for a certain period of time, for example, for about 8 hours to 15 hours under reduced pressure at a temperature range of from about 45°C to about 75°C.
- the drying time can be changed accordingly depending on drying temperature, preferably, drying is done at 45°C to 50°C.
- the isolated crystalline solid refers to substantially pure DMF solvate of the rifaximin.
- the DMF solvate of the rifaximin can be formulated into pharmaceutical compositions with excipients or carriers.
- the various dosage forms which include, but are not limited to, coated or uncoated tablets, hard or soft gelatin capsules, sugar coated pills, lozenges, wafer sheets, pellets, or powders in a sealed packet.
- the DMF solvate of the rifaximin can also be formulated as a topical composition.
- the pharmaceutical composition comprises an amount of DMF solvate of rif-iximin effective to treat, prevent or alleviate the desired indication, i.e., bowel related disorders in an animal, such as a human.
- DMF solvate of the rifaximin as a medicament for treatment, prevention, alleviating bowel related disorders, preferably Travelers' diarrhea and Hepatic encephalopathy.
- the packaging of the DMF solvate of the rifaximin can be done in self sealing polybags under vacuum after nitrogen flushing, or under nitrogen atmosphere, optionally including a desiccant to improve stability of the material.
- preferred embodiments are described by way of examples to illustrate the process. However, these are not intended in any way to limit the scope of the claims. Several variants of these examples would be evident to persons ordinarily skilled in the art.
- the DMF solvate of the rifaximin obtained by the present invention has an HPLC purity greater than 99.1% as measured by area percentage.
- HPLC high performance liquid chromatography
- the XRD pattern was recorded using a PANalytical XPert PRO.
- the TGA and DSC patterns were recorded using TA instruments-Q500 and Mettler DSC 821 e Perkin Elmer, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une nouvelle forme polymorphe de rifaximine connue sous le nom de solvate DMF et son procédé de préparation. L'invention concerne également une composition pharmaceutique la comprenant ainsi que son utilisation pour le traitement de troubles intestinaux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1289DE2011 | 2011-05-02 | ||
PCT/IB2012/052200 WO2012150561A1 (fr) | 2011-05-02 | 2012-05-02 | Solvate de diméthylformamide rifaximine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2705042A1 true EP2705042A1 (fr) | 2014-03-12 |
Family
ID=46124584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12721936.8A Withdrawn EP2705042A1 (fr) | 2011-05-02 | 2012-05-02 | Solvate de diméthylformamide rifaximine |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2705042A1 (fr) |
AU (1) | AU2012251385A1 (fr) |
CA (1) | CA2834829A1 (fr) |
WO (1) | WO2012150561A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2522895T3 (es) | 2005-03-03 | 2014-11-19 | Alfa Wassermann S.P.A. | Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales |
US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
CA2876737A1 (fr) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Formes polymorphes de rifaximine |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
US20140308350A1 (en) | 2013-04-12 | 2014-10-16 | Alfa Wassermann S.P.A. | Nsaid administration and related compositions, methods and systems |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
ES2522895T3 (es) | 2005-03-03 | 2014-11-19 | Alfa Wassermann S.P.A. | Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales |
KR101667534B1 (ko) | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
KR101674382B1 (ko) | 2008-02-25 | 2016-11-09 | 샐릭스 파마슈티컬스 리미티드 | 리팍시민의 형태 및 이의 용도 |
SG185490A1 (en) * | 2010-06-03 | 2012-12-28 | Salix Pharmaceuticals Ltd | New forms of rifaximin and uses thereof |
-
2012
- 2012-05-02 AU AU2012251385A patent/AU2012251385A1/en not_active Abandoned
- 2012-05-02 EP EP12721936.8A patent/EP2705042A1/fr not_active Withdrawn
- 2012-05-02 WO PCT/IB2012/052200 patent/WO2012150561A1/fr active Application Filing
- 2012-05-02 CA CA2834829A patent/CA2834829A1/fr not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2012150561A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2834829A1 (fr) | 2012-11-08 |
WO2012150561A1 (fr) | 2012-11-08 |
AU2012251385A1 (en) | 2013-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2705042A1 (fr) | Solvate de diméthylformamide rifaximine | |
JP2020128380A (ja) | リファキシミン | |
CA2958139A1 (fr) | Formes a l'etat solide d'ibrutinib | |
US8883795B2 (en) | Polymorphic forms of Rifaximin | |
CA2980888C (fr) | Cristal d'un compose d'alcynyle de benzene 3,5-disubstitue | |
WO2009070314A2 (fr) | Forme cristalline de sitagliptine | |
EP2297092A1 (fr) | Formes polymorphes et amorphes de lacosamide et compositions amorphes | |
TW201704234A (zh) | 氮雜二環式化合物之結晶 | |
WO2009120746A2 (fr) | Formes cristallines du phosphate de sitagliptine | |
AU2018371771A1 (en) | Solid state form of Valbenazine | |
AU2017373239A1 (en) | Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof | |
CN111777595A (zh) | 一种环己烷甲酰胺类化合物的新晶型及其制备方法 | |
WO2010016931A2 (fr) | Polymorphes du furoate de fluticasone et leur procédé de préparation | |
WO2017021975A1 (fr) | Procédé de préparation de formes cristallines de rifaximine | |
WO2013027227A1 (fr) | Nouvelle forme polymorphe i de la rifaximine | |
EP3476831B1 (fr) | Forme cristalline de 9-aminométhyle substitués des composés de tetracycline et leur procédé de préparation | |
JP2016533361A (ja) | ピラゾロピリジン化合物の固体形態 | |
CA2596754C (fr) | Melange 1h-imidazo[4,5-b]pyridin-5-amine:sulfate de 7-[5-[(cyclohexylmethylamino)methyl]-1h-indol-2-yl]-2-methyle a (1:1) trihydrate sous forme de cristaux et utilisations pour letraitement de maladies et desordres inflammatoires, autoimmunes et proliferants | |
EP3473623B1 (fr) | Formes cristallines de nbi-98854, procédé de préparation s'y rapportant et utilisation associée | |
CN113045554A (zh) | 一种非索替尼晶型及其制备方法 | |
WO2006117616A1 (fr) | Forme polymorphe de lumefantrine et procedes de preparation | |
CN106916157A (zh) | 取代的氨基吡喃衍生物的晶型 | |
CN114478679A (zh) | 双氢青蒿素-熊去氧胆酸缀合物的多晶型物及其制备方法和应用 | |
JP2008540449A (ja) | (2e,4s)−4−[(n−{[(2r)−1−イソプロピルピペリジン−2−イル]−カルボニル}−3−メチル−l−バリル)(メチル)アミノ]−2,5−ジメチルヘキサ−2−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用 | |
WO2014147641A2 (fr) | Sel de phosphate de sitagliptine et de ptérostilbène, son procédé de préparation et composition pharmaceutique en contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131202 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140624 |